Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Feb 7;109(6):1820-1.
doi: 10.1073/pnas.1121358109. Epub 2012 Jan 30.

Hallucinogen actions on human brain revealed

Hyeong-Min Lee  1 , Bryan L Roth
Affiliations
Comment

Hallucinogen actions on human brain revealed

Hyeong-Min Lee et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Psilocybin diminishes brain activity and connectivity. (A) Psilocybin, which is inactive, is metabolized to the active ingredient psilocin. Psilocin then activates many neurotransmitter receptors (B) to modulate activity on excitatory pyramidal and inhibitory GABA-ergic neurons (C). (B) Affinity values for psilocin are expressed as –log in nanomoles (pKi) and are from the National Institute of Mental Health Psychoactive Drug Screening Programs Ki Database (http://pdsp.med.unc.edu/kidb.php). (C) Psilocin interacts with various receptors on large excitatory pyramidal neurons and smaller inhibitory neurons. Psilocin may interact with excitatory (orange) or inhibitory (red) receptors to augment or inhibit neurotransmission. Psilocin's net effect is a decrease in neuronal activity and connectivity as measured by fMRI.
See this image and copyright information in PMC

Comment on

  • Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
    Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. Carhart-Harris RL, et al. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. doi: 10.1073/pnas.1119598109. Epub 2012 Jan 23. Proc Natl Acad Sci U S A. 2012. PMID: 22308440 Free PMC article. Clinical Trial.

References

    1. Roth BL, et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA. 2002;99:11934–11939. - PMC - PubMed
    1. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505–2511. - PubMed
    1. González-Maeso J, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–452. - PubMed
    1. Keiser MJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–181. - PMC - PubMed
    1. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897–3902. - PubMed

Publication types